Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOSYSEN LIMITED

生物系統工程有限公司

(formerly known as "Legend Strategy International Holdings Group Company Limited
枂濬國際集團控股有限公司")
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1355)

PROPOSED ADOPTION OF SHARE OPTION SCHEME

The board of directors (the "**Board**") of Biosysen Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Board has proposed the adoption of a share option scheme (the "**Share Option Scheme**") for the approval by the shareholders of the Company (the "**Shareholders**").

PROPOSED ADOPTION OF THE SHARE OPTION SCHEME

The Company proposes to adopt the Share Option Scheme in accordance with the requirements under Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") published by The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). The purpose of the Share Option Scheme is to enable the Board to grant share options (the "**Share Options**") thereunder to eligible participants as incentives or rewards for their contribution or potential contribution to the Group.

The adoption of the Share Option Scheme is conditional upon:

(i) the passing of an ordinary resolution by the Shareholders at the general meeting of the Company to approve the adoption of the Share Option Scheme and to authorise the Board to grant Share Options to subscribe for shares (the "**Shares**") of the Company thereunder and to allot and issue Shares pursuant to the exercise of any Share Options; and

(ii) the Listing Committee of the Stock Exchange granting approval for the listing of, and permission to deal in, the Shares to be allotted and issued pursuant to the exercise of any Share Options which may be granted under the Share Option Scheme.

GENERAL

Among other things, an ordinary resolution will be proposed at the forthcoming annual general meeting of the Company (the "**AGM**") for the Shareholders to consider and, if thought fit, approve the adoption of the Share Option Scheme.

A circular containing, among other things, (i) details of the adoption of the Share Option Scheme; (ii) the principal terms of the Share Option Scheme; and (iii) a notice of convening the AGM, is expected to be despatched to the Shareholders in accordance with the requirements of the Listing Rules in due course.

By order of the Board
Biosysen Limited
Lee Tsz Yan
Executive Director

Hong Kong, 28 April 2026

As at the date of this announcement, the Board comprises Mr. Lee Tsz Yan as executive Director; Mr. Cheung Ching Mo and Mr. Hu Xinglong as non-executive Directors; and Mr. Wu Jilin, Mr. Lam Cheung Shing Richard and Mr. So Yin Wai as independent non-executive Directors.